Provided by
| Consensus (mean) in EUR million | FY 2024 | FY 2025 | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|---|
| Orders received | 5,837 | 5,216 | 5,165 | 5,503 | 5,804 |
| - Biomaterial Solutions and Services | 4,392.0 | 3,716.0 | 3,549.7 | 3,678.3 | 3,883.4 |
| - Process Performance Solutions | 1,446.0 | 1,500.0 | 1,616.0 | 1,825.4 | 1,920.5 |
| Net sales | 5,359 | 5,197 | 5,386 | 5,536 | 5,740 |
| - Biomaterial Solutions and Services | 3,922.0 | 3,716.0 | 3,794.8 | 3,735.5 | 3,804.4 |
| - Process Performance Solutions | 1,437.0 | 1,481.0 | 1,595.1 | 1,791.5 | 1,887.9 |
| Comparable EBITA | 609 | 620 | 634 | 699 | 756 |
| - Biomaterial Solutions and Services | 403.0 | 381.0 | 380.5 | 404.2 | 435.9 |
| - Process Performance Solutions | 255.0 | 290.0 | 310.5 | 347.8 | 372.5 |
| Comparable EBITA Margin (%) | 11.4% | 11.9% | 11.8% | 12.6% | 13.2% |
| - Biomaterial Solns. and Servs. | 10.3% | 10.3% | 10.0% | 10.8% | 11.4% |
| - Process Perf. Solns. | 17.7% | 19.6% | 19.5% | 19.4% | 19.8% |
| Reported EPS | 1.52 | 1.52 | 1.60 | 2.15 | 2.43 |
| Dividend per share | 1.35 | 1.35 | 1.41 | 1.48 | 1.54 |